BACKGROUND: Cellular immune suppression is observed in head and neck squamous cell cancer (HNSCC) and contributes to poor prognosis. Restoration of immune homeostasis may require primary cell-derived cytokines at physiologic doses. An immunotherapy regimen containing a biologic, with multiple-active cytokine components, and administered with cytoxan, zinc, and indomethacin was developed to modulate cellular immunity. METHODS: Study methods were designed to determine the safety and efficacy of a 21-day neoadjuvant immunotherapy regimen in a phase 2 trial that enrolled 27 therapy-naïve patients with stage II to IVa HNSCC. Methods included safety, clinical and radiologic tumor response, disease-free survival (DFS), overall survival (OS), and tumor lymphocytic infiltrate (LI) data collection. RESULTS: Acute toxicity was minimal. Patients completed neoadjuvant treatment without surgical delay. By independent radiographic review, 83% had stable disease during treatment. OS was 92%, 73%, and 69% at 12, 24, and 36 months, respectively. Histologic analysis suggested correlation between survival and tumor LI. CONCLUSION: Immunotherapy regimen was tolerated. Survival results are encouraging.
BACKGROUND: Cellular immune suppression is observed in head and neck squamous cell cancer (HNSCC) and contributes to poor prognosis. Restoration of immune homeostasis may require primary cell-derived cytokines at physiologic doses. An immunotherapy regimen containing a biologic, with multiple-active cytokine components, and administered with cytoxan, zinc, and indomethacin was developed to modulate cellular immunity. METHODS: Study methods were designed to determine the safety and efficacy of a 21-day neoadjuvant immunotherapy regimen in a phase 2 trial that enrolled 27 therapy-naïve patients with stage II to IVa HNSCC. Methods included safety, clinical and radiologic tumor response, disease-free survival (DFS), overall survival (OS), and tumor lymphocytic infiltrate (LI) data collection. RESULTS: Acute toxicity was minimal. Patients completed neoadjuvant treatment without surgical delay. By independent radiographic review, 83% had stable disease during treatment. OS was 92%, 73%, and 69% at 12, 24, and 36 months, respectively. Histologic analysis suggested correlation between survival and tumor LI. CONCLUSION: Immunotherapy regimen was tolerated. Survival results are encouraging.
Authors: Scott M Freeman; Jose Luis Barrera Franco; Daniel E Kenady; Lorraine Baltzer; Zygmund Roth; Harvey J Brandwein; John W Hadden Journal: Am J Clin Oncol Date: 2011-04 Impact factor: 2.339
Authors: G T Wolf; S Schmaltz; J Hudson; H Robson; T Stackhouse; K A Peterson; J A Poore; K D McClatchey Journal: Arch Otolaryngol Head Neck Surg Date: 1987-11
Authors: D R Vlock; C H Snyderman; J T Johnson; E N Myers; D E Eibling; J S Rubin; J M Kirkwood; J P Dutcher; G L Adams Journal: J Immunother Emphasis Tumor Immunol Date: 1994-02
Authors: Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos Journal: N Engl J Med Date: 2003-01-16 Impact factor: 91.245
Authors: B Schilling; E S Halstead; P Schuler; M Harasymczuk; J E Egan; T L Whiteside Journal: Cancer Immunol Immunother Date: 2012-01-20 Impact factor: 6.968
Authors: Neil L Berinstein; Gregory T Wolf; Paul H Naylor; Lorraine Baltzer; James E Egan; Harvey J Brandwein; Theresa L Whiteside; Lynn C Goldstein; Adel El-Naggar; Cecile Badoual; Wolf-Herve Fridman; J Michael White; John W Hadden Journal: Cancer Immunol Immunother Date: 2011-11-06 Impact factor: 6.968
Authors: Theresa L Whiteside; Lisa H Butterfield; Paul H Naylor; James E Egan; John W Hadden; Lorraine Baltzer; Gregory T Wolf; Neil L Berinstein Journal: Cancer Immunol Immunother Date: 2011-11-23 Impact factor: 6.968
Authors: Ramez Philips; Chihun Han; Brian Swendseid; Joseph Curry; Athanassios Argiris; Adam Luginbuhl; Jennifer Johnson Journal: Front Oncol Date: 2021-07-01 Impact factor: 6.244